Peptide Profile
BPC-157
Synthetic Gastric Pentadecapeptide
CLINICAL DEVELOPMENT STAGE:
Phase 1
BPC-157 is an investigational 15-amino-acid gastric peptide studied primarily for gastrointestinal integrity, tissue repair, angiogenesis, musculoskeletal healing, and inflammatory signaling.
Compound Overview
Molecular Formula
C₆₂H₉₈N₁₆O₂₂
Molecular Weight
1419.5 g/mol
CAS Number
137525-51-0
Classification
Synthetic Gastric Pentadecapeptide
Regulatory Status
Investigational; not FDA approved.
Targets / Receptors
No single established primary receptor; VEGF-related angiogenic signaling, nitric oxide pathways, growth-factor signaling, inflammatory pathways, and vascular signaling have been investigated.
Research Focus
Gastrointestinal mucosal integrity; tissue repair; angiogenesis; tendon and ligament healing; musculoskeletal recovery; nitric oxide signaling; inflammatory pathway modulation; vascular response
Mechanism of Action
BPC-157 is a 15-amino-acid peptide derived from a sequence associated with gastric proteins. Its mechanism of action has not been definitively established, and much of the proposed mechanistic evidence comes from animal and laboratory studies.
Preclinical research suggests BPC-157 may influence angiogenic signaling, nitric oxide pathways, vascular responses, inflammatory signaling, and extracellular tissue repair. Studies have also examined interactions with growth-factor-related pathways involved in tendon, ligament, muscle, bone, and gastrointestinal tissue repair.
Because no single receptor has been established as the primary pharmacological target of BPC-157, its reported biological effects are better described as multi-pathway signaling effects rather than activity at one defined receptor.
Research Evidence
The evidence base for BPC-157 remains predominantly preclinical. A 2025 systematic review of musculoskeletal research identified 36 eligible studies, of which 35 were preclinical and only one was a clinical study. Animal models have reported effects involving tendon, ligament, muscle, bone, and other tissue-repair processes, but these findings cannot be assumed to establish equivalent effects in humans.
Human exposure has occurred, but the clinical evidence is small and limited. FDA’s 2026 review identified small studies involving healthy volunteers and patients with ulcerative colitis, knee pain, and interstitial cystitis, along with two healthy subjects who received intravenous BPC-157. FDA noted that sample sizes were small, study durations were short, and safety monitoring was limited or unclear in several studies.
A Phase 1 trial was registered to evaluate oral BPC-157 safety and pharmacokinetics in healthy volunteers, but the ClinicalTrials.gov record has not been updated since 2015 and currently carries an unknown status. Overall, controlled human evidence remains insufficient to establish therapeutic efficacy or a well-characterized long-term safety profile.
Safety & Limitations
BPC-157 is not FDA approved, and its human safety profile has not been adequately characterized. Most published evidence comes from animal or laboratory studies, while available human studies involve small populations and limited follow-up.
FDA has specifically noted concerns related to limited human safety information, possible immunogenicity, peptide aggregation, peptide-related impurities, and challenges in active pharmaceutical ingredient characterization. These concerns are especially relevant when extrapolating experimental findings to compounded or otherwise unapproved preparations.
Reported preclinical findings should therefore not be interpreted as proof of safety or efficacy in humans. Long-term effects, clinically meaningful efficacy, pharmacokinetics across different formulations, and risks associated with different routes of exposure remain incompletely characterized.
Key References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee: BPC-157 Review. FDA. 2026.
- ClinicalTrials.gov. PCO-02 – Safety and Pharmacokinetics Trial, NCT02637284. Phase 1 clinical trial.
- National Center for Biotechnology Information. BPC-157, PubChem CID 9941957. PubChem.
Last scientifically reviewed: September 4, 2026
